197 related articles for article (PubMed ID: 11504783)
1. Inhibition of tumor necrosis factor-alpha (TNF-alpha) production and arthritis in the rat by GW3333, a dual inhibitor of TNF-alpha-converting enzyme and matrix metalloproteinases.
Conway JG; Andrews RC; Beaudet B; Bickett DM; Boncek V; Brodie TA; Clark RL; Crumrine RC; Leenitzer MA; McDougald DL; Han B; Hedeen K; Lin P; Milla M; Moss M; Pink H; Rabinowitz MH; Tippin T; Scates PW; Selph J; Stimpson SA; Warner J; Becherer JD
J Pharmacol Exp Ther; 2001 Sep; 298(3):900-8. PubMed ID: 11504783
[TBL] [Abstract][Full Text] [Related]
2. Characterization of (2R, 3S)-2-([[4-(2-butynyloxy)phenyl]sulfonyl]amino)-N,3-dihydroxybutanamide, a potent and selective inhibitor of TNF-alpha converting enzyme.
Zhang Y; Hegen M; Xu J; Keith JC; Jin G; Du X; Cummons T; Sheppard BJ; Sun L; Zhu Y; Rao VR; Wang Q; Xu W; Cowling R; Nickerson-Nutter CL; Gibbons J; Skotnicki J; Lin LL; Levin J
Int Immunopharmacol; 2004 Dec; 4(14):1845-57. PubMed ID: 15531300
[TBL] [Abstract][Full Text] [Related]
3. TACE inhibition: a new approach to treating inflammation.
Doggrell SA
Expert Opin Investig Drugs; 2002 Jul; 11(7):1003-6. PubMed ID: 12084010
[TBL] [Abstract][Full Text] [Related]
4. Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis.
Zhang Y; Xu J; Levin J; Hegen M; Li G; Robertshaw H; Brennan F; Cummons T; Clarke D; Vansell N; Nickerson-Nutter C; Barone D; Mohler K; Black R; Skotnicki J; Gibbons J; Feldmann M; Frost P; Larsen G; Lin LL
J Pharmacol Exp Ther; 2004 Apr; 309(1):348-55. PubMed ID: 14718605
[TBL] [Abstract][Full Text] [Related]
5. CYP3A induction by N-hydroxyformamide tumor necrosis factor-alpha converting enzyme/matrix metalloproteinase inhibitors use of a pregname X receptor activation assay and primary hepatocyte culture for assessing induction potential in humans.
Tippin TK; Hamilton G; Moore L; Beaudet EJ; Jolley S; Brodie TA; Andrews RC; Becherer JD; McDougald DL; Gaul MD; Hoivik DJ; Mellon-Kusibab K; Lehmann J; Kliewer S; Novick S; Laethem R; Zhao Z; LeCluyse EL
Drug Metab Dispos; 2003 Jul; 31(7):870-7. PubMed ID: 12814963
[TBL] [Abstract][Full Text] [Related]
6. Differential effects between marimastat, a TNF-alpha converting enzyme inhibitor, and anti-TNF-alpha antibody on murine models for sepsis and arthritis.
Tsuji F; Oki K; Okahara A; Suhara H; Yamanouchi T; Sasano M; Mita S; Horiuchi M
Cytokine; 2002 Mar; 17(6):294-300. PubMed ID: 12061836
[TBL] [Abstract][Full Text] [Related]
7. (E)-2(R)-[1(S)-(Hydroxycarbamoyl)-4-phenyl-3-butenyl]-2'-isobutyl-2'-(methanesulfonyl)-4-methylvalerohydrazide (Ro 32-7315), a selective and orally active inhibitor of tumor necrosis factor-alpha convertase.
Beck G; Bottomley G; Bradshaw D; Brewster M; Broadhurst M; Devos R; Hill C; Johnson W; Kim HJ; Kirtland S; Kneer J; Lad N; Mackenzie R; Martin R; Nixon J; Price G; Rodwell A; Rose F; Tang JP; Walter DS; Wilson K; Worth E
J Pharmacol Exp Ther; 2002 Jul; 302(1):390-6. PubMed ID: 12065742
[TBL] [Abstract][Full Text] [Related]
8. Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
Rabinowitz MH; Andrews RC; Becherer JD; Bickett DM; Bubacz DG; Conway JG; Cowan DJ; Gaul M; Glennon K; Lambert MH; Leesnitzer MA; McDougald DL; Moss ML; Musso DL; Rizzolio MC
J Med Chem; 2001 Nov; 44(24):4252-67. PubMed ID: 11708926
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological profile of PKF242-484 and PKF241-466, novel dual inhibitors of TNF-alpha converting enzyme and matrix metalloproteinases, in models of airway inflammation.
Trifilieff A; Walker C; Keller T; Kottirsch G; Neumann U
Br J Pharmacol; 2002 Apr; 135(7):1655-64. PubMed ID: 11934805
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of DPC 333 ((2R)-2-((3R)-3-amino-3{4-[2-methyl-4-quinolinyl) methoxy] phenyl}-2-oxopyrrolidinyl)-N-hydroxy-4-methylpentanamide)), a potent and selective inhibitor of tumor necrosis factor alpha-converting enzyme in rodents, dogs, chimpanzees, and humans.
Qian M; Bai SA; Brogdon B; Wu JT; Liu RQ; Covington MB; Vaddi K; Newton RC; Fossler MJ; Garner CE; Deng Y; Maduskuie T; Trzaskos J; Duan JJ; Decicco CP; Christ DD
Drug Metab Dispos; 2007 Oct; 35(10):1916-25. PubMed ID: 17656469
[TBL] [Abstract][Full Text] [Related]
11. Effect of a matrix metalloproteinase activity and TNF-alpha converting enzyme inhibitor on intra-abdominal adhesions.
Mirastschijski U; Johannesson K; Jeppsson B; Agren MS
Eur Surg Res; 2005; 37(1):68-75. PubMed ID: 15818044
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of matrix metalloproteinases and tumour necrosis factor alpha converting enzyme as adjuvant therapy in pneumococcal meningitis.
Leib SL; Clements JM; Lindberg RL; Heimgartner C; Loeffler JM; Pfister LA; Täuber MG; Leppert D
Brain; 2001 Sep; 124(Pt 9):1734-42. PubMed ID: 11522576
[TBL] [Abstract][Full Text] [Related]
13. Blockade of tumor necrosis factor-alpha-converting enzyme improves experimental small intestinal damage by decreasing matrix metalloproteinase-3 production in rats.
Matsumoto H; Koga H; Iida M; Tarumi K; Fujita M; Haruma K
Scand J Gastroenterol; 2006 Nov; 41(11):1320-9. PubMed ID: 17060126
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of cartilage and bone destruction in adjuvant arthritis in the rat by a matrix metalloproteinase inhibitor.
Conway JG; Wakefield JA; Brown RH; Marron BE; Sekut L; Stimpson SA; McElroy A; Menius JA; Jeffreys JJ; Clark RL
J Exp Med; 1995 Aug; 182(2):449-57. PubMed ID: 7629505
[TBL] [Abstract][Full Text] [Related]
15. Importance of tumor necrosis factor-alpha cleavage process in post-transplantation lung injury in rats.
Goto T; Ishizaka A; Kobayashi F; Kohno M; Sawafuji M; Tasaka S; Ikeda E; Okada Y; Maruyama I; Kobayashi K
Am J Respir Crit Care Med; 2004 Dec; 170(11):1239-46. PubMed ID: 15333331
[TBL] [Abstract][Full Text] [Related]
16. Sulfonate ester hydroxamic acids as potent and selective inhibitors of TACE enzyme.
Levin JI; Du MT
Drug Des Discov; 2003; 18(4):123-6. PubMed ID: 15553924
[TBL] [Abstract][Full Text] [Related]
17. Beta-aryl-succinic acid hydroxamates as dual inhibitors of matrix metalloproteinases and tumor necrosis factor alpha converting enzyme.
Kottirsch G; Koch G; Feifel R; Neumann U
J Med Chem; 2002 May; 45(11):2289-93. PubMed ID: 12014967
[TBL] [Abstract][Full Text] [Related]
18. Tumour necrosis factor-alpha converting enzyme (TACE) activity in human colonic epithelial cells.
Kirkegaard T; Pedersen G; Saermark T; Brynskov J
Clin Exp Immunol; 2004 Jan; 135(1):146-53. PubMed ID: 14678276
[TBL] [Abstract][Full Text] [Related]
19. A comparison of the binding sites of matrix metalloproteinases and tumor necrosis factor-alpha converting enzyme: implications for selectivity.
Lukacova V; Zhang Y; Kroll DM; Raha S; Comez D; Balaz S
J Med Chem; 2005 Apr; 48(7):2361-70. PubMed ID: 15801829
[TBL] [Abstract][Full Text] [Related]
20. Anti-arthritic activity of hydroxamic acid-based pseudopeptide inhibitors of matrix metalloproteinases and TNF alpha processing.
DiMartino M; Wolff C; High W; Stroup G; Hoffman S; Laydon J; Lee JC; Bertolini D; Galloway WA; Crimmin MJ; Davis M; Davies S
Inflamm Res; 1997 Jun; 46(6):211-5. PubMed ID: 9243304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
